Frontlight ResearchEarly access
Trial site
Harzklinikum Dorothea Christiane Erxleben GmbH
- 7running trials
- 4closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Conditions
- Melanoma5 trials
- Childhood cancers3 trials
- Atopic dermatitis (eczema)2 trials
- Psoriasis2 trials
- Atrial fibrillation1 trial
- Hidradenitis suppurativa1 trial
- Phase
- Phase 24 trials
- Phase 34 trials
- Phase 2/31 trial
- Status
- Active, not recruiting4 trials
- Completed4 trials
- Recruiting3 trials
- Lead sponsor
- Bristol-Myers Squibb2 trials
- Hoffmann-La Roche2 trials
- Regeneron Pharmaceuticals2 trials
- Abbott Medical Devices1 trial
- Arctic Bioscience AS1 trial
- and 3 more
Running trials
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
Active, not recruiting
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Atopic dermatitis (eczema)1 recruiting
- Childhood cancers1 recruiting
- Melanoma1 recruiting
- Psoriasis1 recruiting
Closed trials
Completed
Completed
Completed
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients
Completed
Site data: EU CTIS (euclinicaltrials.eu)Updated 18 Nov 2026